Karnataka Antibiotics & Pharmaceuticals Ltd., (KAPL) Bangalore is a Government Enterprise. From a modest beginning in 1984, KAPL has grown from strength to strength in the areas of manufacturing and marketing of various life saving and essential drugs. With an ISO accredition from KPMG, Netherlands, KAPL is recognised for its total commitment to quality and services in domestic and international markets. On profit from inception, KAPL facilities are approved by many international clients.
Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19.